Table 1.
Details of drugs combined with bevacizumab
| Combination drugs | Number of patients | Regimens |
|---|---|---|
| Group A | n = 44 | |
| Gemcitabine and oxaliplatin | 24 | 400 mg/m2 gemcitabine and 40 mg/m2 oxaliplatin on days 1, 8, and 15 |
| Pegylated liposomal doxorubicin | 10 | 10 mg/m2 pegylated liposomal doxorubicin on days 1, 8, and 15 |
| Eribulin and oxaliplatin | 5 | 1 mg/m2 eribulin and 40 mg/m2 oxaliplatin on days 1, 8, and 15 |
| Nivolumab | 1 | 100 mg nivolumab on days 1 and 15, every 4 weeks |
| Paclitaxel and carboplatin | 1 | 175 mg/m2 paclitaxel and AUC 5 carboplatin on day 1 |
| Paclitaxel | 1 | 80 mg/m2 paclitaxel on days 1, 8, and 15 |
| Trabectedin and oxaliplatin | 1 | 0.25 mg/m2 trabectedin and 40 mg/m2 oxaliplatin on days 1, 8, and 15 |
| Trabectedin and pegylated liposomal doxorubicin | 1 | 10 mg/m2 pegylated liposomal doxorubicin and 0.25 mg/m2 trabectedin on days 1, 8, and 15 |
| Group B | n = 33 | |
| Gemcitabine | 32 | 1000 mg/m2 gemcitabine on days 1, 8, and 15 |
| Paclitaxel | 1 | 80 mg/m2 paclitaxel on days 1, 8, and 15 |
Group A was defined as patients treated with weekly low-dose administration of bevacizumab
Group B was defined as patients treated with monthly high-dose administration of bevacizumab
AUC Area under the curve